Abstract:

Objective To investigate the clinical efficacy of early administration of aminophylline on improving brain injury in preterm infants by evaluating neuron⁃specific enolase（NSE）. Methods Data of critical newborns admitted to NICU from September 2018 to September 2020 who had at least twice NSE test results within 5 days after birth were collected. Results 30 newborns who were treated with intravenous aminophylline were clas⁃ sified into the treatment group，while 54 newborns who were untreated with aminophylline in the early stage were classified into the control group. The average daily decrease of the brain injury markers NSE between two groups was compared. Compared with the control group，the daily average decrease of NSE in the treatment group was sig⁃ nificantly larger. In order to exclude the influence of confounding factors，the subgroup further analyzed that in the cases of severe brain injury with NSE > 60 ng/mL，the average daily decrease of NSE in the treatment group was still significantly larger than that in the control group. In the cases of mild brain injury with NSE <60 ng/mL，the average daily decrease of NSE in the treatment group was larger than that of the control group，however，there was no significantly difference. There was no significant difference in the overall incidence of adverse events between two groups. Conclusion Administration of aminophylline in the early stage is beneficial to the recovery of critical newborns brain injury，especially in the severe brain injury case. 

Key words:

premature brain injury, aminophylline, neuron?specific enolase